New England Journal of Medicine· 2012Q1· Clinical trial

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin et al.

4,593citations
Q1SCImago
2012year

Short summary

Enzalutamide significantly extended overall survival by 4.8 months in men with metastatic castration-resistant prostate cancer post-chemotherapy, compared to placebo.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine